SEC Form 4 · accession 0001104659-17-072537
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Y Chan
Officer — See Remarks
Period of report
Dec 6, 2017
Accepted (ET)
Dec 8, 2017 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2,F3 | Dec 6, 2017 | F | 1,216 | $3.33 | D | 13,784 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
- F2The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of 3,750 restricted stock units on December 6, 2017.
- F3This total includes 11,250 unvested restricted stock units which were granted on December 6, 2016 and were reported in Table II, as well as the shares settled after the tax withholding and vesting event described in footnote number 2. Each restricted stock unit represents a contingent right to receive one common share of the Issuer.
Remarks
President and Chief Accounting Officer of Aegerion Pharmaceuticals, Inc.